Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") will present new exploratory analyses from the global Phase 3 SCORPIO-PEP study, ...

Ascentage Pharma receives China's Breakthrough Therapy Designation for lisaftoclax plus acalabrutinib in untreated CLL/SLL as ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical ...

Shanghai, China - October 16, 2026 - MicroPort Scientific Corporation announced that it and its associated companies have reached a cumulative total of 50 products accepted into China's National ...

Envoy has submitted 2 of 4 planned FDA modules and expects to submit its final trial-data module by end-Q2 2027; 12-month ...

The 13-point charter also called for the restoration of GSCASH, the return of JNUEE and action on wider concerns over campus ...

Ascentage Pharma Group International announced that lisaftoclax (APG-2575), the Company's novel Bcl-2 inhibitor, has been granted a Breakthrough Therapy Designation (BTD) by the Center for Drug ...

We break down the first FDA-approved myopia treatment glasses, candidate eligibility for kids, and daily wear expectations.

More consumer wellness companies are pursuing FDA clearance, and the timing of that decision reveals their strategy.

Second of Four Planned Modules Moves Rolling FDA Review Forward Advances Toward Targeted Completion of the Final Clinical ...

New research spotlights hypoglycemia-related burdens in adults with type 1 diabetes using automated insulin delivery systems HIGH POINT, N.C., Oct. 10, 2026 (GLOBE NEWSWIRE) ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...